Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 14:12:616272.
doi: 10.3389/fneur.2021.616272. eCollection 2021.

Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntington's Disease

Affiliations

Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntington's Disease

Nina M Mansoor et al. Front Neurol. .

Abstract

Background: Neuroimaging shows considerable promise in generating sensitive and objective outcome measures for therapeutic trials across a range of neurodegenerative conditions. For volumetric measures the current gold standard is manual delineation, which is unfeasible for samples sizes required for large clinical trials. Methods: Using a cohort of early Huntington's disease (HD) patients (n = 46) and controls (n = 35), we compared the performance of four automated segmentation tools (FIRST, FreeSurfer, STEPS, MALP-EM) with manual delineation for generating cross-sectional caudate volume, a region known to be vulnerable in HD. We then examined the effect of each of these baseline regions on the ability to detect change over 15 months using the established longitudinal Caudate Boundary Shift Integral (cBSI) method, an automated longitudinal pipeline requiring a baseline caudate region as an input. Results: All tools, except Freesurfer, generated significantly smaller caudate volumes than the manually derived regions. Jaccard indices showed poorer levels of overlap between each automated segmentation and manual delineation in the HD patients compared with controls. Nevertheless, each method was able to demonstrate significant group differences in volume (p < 0.001). STEPS performed best qualitatively as well as quantitively in the baseline analysis. Caudate atrophy measures generated by the cBSI using automated baseline regions were largely consistent with those derived from a manually segmented baseline, with STEPS providing the most robust cBSI values across both control and HD groups. Conclusions: Atrophy measures from the cBSI were relatively robust to differences in baseline segmentation technique, suggesting that fully automated pipelines could be used to generate outcome measures for clinical trials.

Keywords: FIRST; FreeSurfer; Huntington (disease); MALP-EM; STEPS; automated segmentation; caudate.

PubMed Disclaimer

Conflict of interest statement

ER was employed by UCL during the period of data collection and image processing. She now works for IXICO plc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Boxplots showing caudate volumes separated by group for each segmentation tool including manual segmentation. Boxes show first quartile, median and third quartile with whiskers representing the smallest and largest volumes. Dots represent outliers. Independent t-tests for each method demonstrated significant volume differences at 95% CI between the two groups, all p < 0.0001.
Figure 2
Figure 2
Boxplot demonstrating caudate volume outputs by disease state (HD=1, Controls=0) and site. Boxes show first quartile, median and third quartile with whiskers represent the smallest and largest volumes. Dots represent outliers. More outliers were found at the Ulm site.
Figure 3
Figure 3
Boxplot demonstrating Jaccard Indices (as a ratio) for each automated method ROI with manual ROI. Boxes show first quartile, median and third quartile with whiskers represent the smallest and largest volumes. Dots represent outliers. STEPS segmented ROIs had larger overlaps with manually segmented ROI in both controls and HD subjects (closest to 1).

References

    1. Huntington’s Disease Collaborative Research Group . A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell. (1993) 72:971–83. 10.1016/0092-8674(93)90585-E - DOI - PubMed
    1. Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, et al. . Huntington disease. Nat Rev Dis Primers. (2015) 1:1–21. 10.1038/nrdp.2015.5 - DOI - PubMed
    1. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP, Jr. Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol. (1985) 44:559–77. 10.1097/00005072-198511000-00003 - DOI - PubMed
    1. Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington’s disease. Lancet Neurol. (2017) 16:837–47. 10.1016/S1474-4422(17)30280-6 - DOI - PMC - PubMed
    1. Yang S, Chang R, Yang H, Zhao T, Hong Y, Kong HE, et al. . CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease. J Clin Investigation. (2017) 127:2719–24. 10.1172/JCI92087 - DOI - PMC - PubMed

LinkOut - more resources